Search

Displaying results 5961 - 5970 of 10000 in total
  1. Drug

    MPT0B640

    go.drugbank.com/drugs/DB16512
    Investigational

    MPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.

  2. Drug

    Resolvin E1

    go.drugbank.com/drugs/DB13105
    Investigational

    Resolvin E1 (RX 10001) is under investigation in clinical trial NCT00941018 (Single and Multiple Ascending Oral Dose Study of Resolvin E1 in Healthy Volunteers).

  3. Drug

    αAβ–Gas6

    go.drugbank.com/drugs/DB17069
    Experimental

    for receptor kinases expressed in glial cells. … αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD).

  4. Drug

    2-Methoxyestradiol

    go.drugbank.com/drugs/DB02342
    Investigational

    2-Methoxyestradiol (2ME2) is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis).

  5. Drug

    Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10598
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  6. Drug

    Influenza B virus B/Phuket/3073/2013 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10599
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  7. Drug

    Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB10601
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  8. Drug

    Influenza A virus A/California/7/2009 (H1N1) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10773
    ApprovedInvestigationalWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  9. Drug

    Influenza A virus A/Christchurch/16/2010 NIB-74XP (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10996
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  10. Drug

    Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11038
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.